Xue Fei, Zhou Yating
Kunshan Hospital of Traditional Chinese Medicine, 388 Zuchongzhi South Road, Kunshan City, Suzhou, Jiangsu Province, China.
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 19. doi: 10.1007/s00417-025-06800-1.
With the rapid global rise of myopia, glaucoma, AMD, and dry eye disease, red light therapy (RLT) is quickly emerging as a non-invasive, breakthrough approach with extraordinary potential to transform eye health management. Originally applied for wound healing and pain relief, RLT has shown remarkable, multi-faceted effects in ophthalmology: slowing myopia progression, protecting retinal cells in glaucoma, reducing inflammation in AMD, and relieving symptoms of dry eye disease. However, alongside the surge in research interest, questions regarding optimal dosing, safety, and standardization remain pressing. This review summarizes the latest advances of RLT in eye health, explores its mechanisms of action, analyzes safety concerns in clinical applications, and discusses its synergistic potential with existing treatment methods as well as the integration of RLT with artificial intelligence and wearable technologies. In the future, RLT is expected to play a significant role in the management of chronic ocular diseases, but its long-term effects and safety need careful evaluation, with challenges also remaining in regulatory policies and clinical standardization.
随着全球近视、青光眼、年龄相关性黄斑变性和干眼病的迅速增加,红光疗法(RLT)正迅速成为一种非侵入性的、具有变革眼部健康管理非凡潜力的突破性方法。RLT最初应用于伤口愈合和疼痛缓解,现已在眼科领域显示出显著的多方面效果:减缓近视进展、保护青光眼患者的视网膜细胞、减轻年龄相关性黄斑变性的炎症以及缓解干眼病症状。然而,随着研究兴趣的激增,关于最佳剂量、安全性和标准化的问题仍然紧迫。本综述总结了RLT在眼部健康方面的最新进展,探讨了其作用机制,分析了临床应用中的安全问题,并讨论了其与现有治疗方法的协同潜力以及RLT与人工智能和可穿戴技术的整合。未来,RLT有望在慢性眼病的管理中发挥重要作用,但其长期效果和安全性需要仔细评估,监管政策和临床标准化方面也仍存在挑战。